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INTRODUCTION 
 
Today, breast cancer treatment requires a multi-
disciplinary approach, involving an extensive medical  
 
team consisting of specialized surgeons, medical 
oncologists, oncology nurses, as well as radiologists and 
radiology technicians, to perform anti-cancer therapy, 
which consists of tumor excision, chemo- or hormonal-
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ABSTRACT 
 
Cancer stem cells (CSCs) have been proposed to be responsible for tumor recurrence, distant metastasis and 
drug-resistance, in the vast majority of cancer patients. Therefore, there is an urgent need to identify new drugs 
that can target and eradicate CSCs. To identify new molecular targets that are unique to CSCs, we previously 
compared MCF7 2D-monolayers with 3D-mammospheres, which are enriched in CSCs. We observed that 25 
mitochondrial-related proteins were >100-fold over-expressed in 3D-mammospheres. Here, we used these 25 
proteins to derive short gene signatures to predict distant metastasis (in N=1,395 patients) and tumor 
recurrence (in N=3,082 patients), by employing a large collection of transcriptional profiling data from ER(+) 
breast cancer patients. This analysis resulted in a 4-gene signature for predicting distant metastasis, with a 
hazard ratio of 1.91-fold (P=2.2e-08). This provides clinical evidence to support a role for CSC mitochondria in 
metastatic dissemination. Next, we employed a panel of mitochondrial inhibitors, previously shown to target 
mitochondria and selectively inhibit 3D-mammosphere formation in MCF7 cells and cell migration in MDA-MB-
231 cells. Remarkably, these five mitochondrial inhibitors had only minor effects or no effect on MDA-MB-231 
tumor formation, but preferentially and selectively inhibited tumor cell metastasis, without causing significant 
toxicity. Mechanistically, all five mitochondrial inhibitors have been previously shown to induce ATP-depletion 
in cancer cells. Since 3 of these 5 inhibitors were designed to target the large mitochondrial ribosome, we next 
interrogated whether genes encoding the large mitochondrial ribosomal proteins (MRPL) also show prognostic 
value in the prediction of distant metastasis in both ER(+) and ER(-) breast cancer patients. Interestingly, gene 
signatures composed of 6 to 9 MRPL mRNA-transcripts were indeed sufficient to predict distant metastasis, 
tumor recurrence and Tamoxifen resistance. These gene signatures could be useful as companion diagnostics to 
assess which patients may benefit most from anti-mito-ribosome therapy. Overall, our studies provide the 
necessary proof-of-concept, and in vivo functional evidence, that mitochondrial inhibitors can successfully and 
selectively target the biological process of cancer cell metastasis. Ultimately, we envision that mitochondrial 
inhibitors could be employed to develop new treatment protocols, for clinically providing metastasis 
prophylaxis, to help prevent poor clinical outcomes in cancer patients. 
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therapy, as well as radiation therapy. Despite these 
major advances, many patients still ultimately undergo 
treatment failure, in the form of tumor recurrence and 
distant metastasis. Unfortunately, distant metastasis 
causes premature death, in >90% of cancer patients with 
treatment failure [1–5]. Therefore, there is a clear need 
to develop new strategies to prevent cancer cell 
metastasis.  
 
Local and distant metastases are thought to be caused 
by a small sub-population of cancer cells, known as 
cancer stem cells (CSCs) [1–5]. These CSCs are 
unique, in the sense that they can regenerate tumors 
in immune-deficient mice, as xenografts, and they 
undergo anchorage-independent proliferation and the 
EMT, allowing them to disseminate throughout the 
body, thereby creating local and distant metastatic 
lesions, which are largely chemo- and radio-therapy 
resistant [1–5]. However, it remains largely 
unknown, what are the precise vulnerabilities of 
CSCs.  
 
Recently, we identified cancer cell mitochondria as a 
new promising therapeutic target for the eradication 
of CSCs [6–8]. New evidence suggests that CSCs 
have elevated levels of mitochondrial biogenesis, that 
helps to energetically drive their rapid propagation 
and anchorage-independent growth [6–10]. In support 
of this notion, metastatic breast cancer cells in 
positive lymph nodes, removed from patients, show a 
significant increase in mitochondrial Complex IV 
activity, as seen by histochemical- and immuno-
staining [11, 12].  
 
Importantly, mitochondrial biogenesis is strictly 
dependent on the function of the mitochondrial 
ribosome, which consists of both large and small 
subunits, to effectively carry out the mitochondrial 
protein translation of 13 key genes that are absolutely 
required for OXPHOS and mitochondrial ATP 
production [13]. Interestingly, in eukaryotic cells, 
mitochondria originally evolved from engulfed aerobic 
bacteria, an event estimated to have occurred 
approximately 1.5 billion years ago. Because of this 
close evolutionary relationship, certain FDA-approved 
drugs inhibit mitochondrial protein translation as an off-
target side effect. For example, Doxycycline (a 
Tetracycline family member) negatively affects the 
small mito-ribosome, while Azithromycin (an 
Erythromycin family member) inhibits the large mito-
ribosome. Both Doxycycline and Azithromycin 
effectively inhibit the anchorage-independent 
propagation of CSCs, as assessed using the 3D-tumor-
sphere assay, in 12 cell lines derived from 8 different 
cancer types, including breast cancers (MCF7, T47D, 
MDA-MB-231 and MCF10.DCIS.COM) [13]. 
Therefore, we proposed that these off-target side-effects 
could be clinically “re-purposed” as a therapeutic effect.  
 
A recent Phase II clinical trial also showed that 
Doxycycline treatment (200-mg/day for 2-weeks) of 
early stage breast cancer patients reduced their CSC 
tumor load (as assessed by CD44 immuno-staining), 
between ~17% and ~67%, with a positive response rate 
approaching nearly 90% [14]. Therefore, inhibition of 
mitochondrial protein translation may be a new valuable 
target for eradicating CSCs in patients [14].  
 
To design novel therapeutics to more effectively target 
the mitochondria, we used the known 3D-structure of 
the large mammalian mito-ribosome, to perform in 
silico library screening, coupled with phenotypic drug 
screening, to develop a new family of drug-like 
compounds, called the Mitoriboscins [15]. Importantly, 
as predicted, the Mitoriboscins inhibited mitochondrial 
oxygen consumption rates, resulting in cellular ATP-
depletion, and potently inhibited 3D-mammosphere 
formation, all with an IC-50 in the low micro-molar 
range [15]. 
 
Here, we now show that the Mitoriboscins have only 
minor effects (23/G4) or no inhibitory effects (24/D4, 
24/F9) on tumor growth, but functionally prevent 
metastatic progression. Quantitatively similar results 
were obtained with another independent class of 
mitochondrial inhibitors, namely Butene-1,4-bis-
triphenyl-phosphonium (Bis-TPP) and Dodecyl-
triphenyl-phosphonium (Dodecyl-TPP) [16, 17]. Bis-TPP 
and Dodecyl-TPP both contain a TPP moiety, which 
functions as a chemical signal for mitochondrial targeting 
[16, 17]. These data provide in vivo functional evidence 
that five mitochondrial inhibitors can successfully and 
preferentially target the biological process of cancer cell 
metastasis, without significant toxicity.  
 
RESULTS 
 
Cancer stem cell (CSC) based mitochondrial 
signatures for predicting distant metastasis and 
tumor recurrence 
 
After a breast cancer diagnosis, most patients undergo 
surgical resection of the primary tumor and are then 
subsequently treated with hormone-, chemo- and/or 
radio-therapy, depending on the breast cancer subtype. 
However, many patients ultimately experience 
treatment failure, resulting in tumor recurrence and 
distant metastasis. Unfortunately, distant metastasis is 
responsible for the premature deaths in the vast majority 
of cancer patients, approaching >90% (Figure 1). 
Therefore, new diagnostics and therapeutics are 
urgently needed to prevent and treat metastatic disease, 
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which has been attributed to the existence and 
resurgence of a small sub-population of cancer cells, 
known as cancer stem cells (CSCs).  
 
In order to identify new molecular targets that are 
selectively up-regulated in CSCs, we previously carried 
out unbiased proteomics analysis on MCF7 cell 2D-
monolayers, as directly compared with MCF7 3D-
mammospheres, which are known to be highly enriched 
in CSCs and progenitor cells [6]. As a consequence, we 
observed that 25 mitochondrial proteins were highly up-
regulated by >100-fold, specifically in 3D-
mammospheres [6]. 
 
Here, we interrogated whether the mRNA transcripts of 
these mitochondrial proteins show any prognostic value 
in large numbers of ER(+) human breast cancer 
patients. Interestingly, we observed that 13 of these 25 
gene transcripts showed prognostic value in predicting 
distant metastasis. We then used these 13 gene 
transcripts to create a mitochondrial-related gene 
signature, that effectively predicted distant metastasis  
in 1,395 patients (HR=1.79; P=3.4e-07). See Sup-
plementary Table 1 and Figure 2.  
 
To optimize its predictive value, we next selected the 
top 4 gene transcripts, with the largest hazard ratios, to 
construct a short 4-gene signature, which revealed an 
increase in prognostic value, related to distant  
 
 
 
Figure 1. Clinical course of cancer therapy: Focus on the 
causes of treatment failure. After diagnosis, breast cancer 
patients undergo surgical resection of the primary tumor and 
then are treated with a specific therapy (hormone/chemo/radio), 
depending on the breast cancer subtype and clinical staging. 
However, a significant number of patients ultimately undergo 
treatment failure, resulting in tumor recurrence and distant 
metastasis. Distant metastasis is responsible for the premature 
deaths of >90% of cancer patients, undergoing treatment failure. 
This phenomenon has been attributed to the propagation and 
dissemination of CSCs.  
metastasis (HR=1.91; P=2.2e-08). Remarkably, this 4-
gene signature was also able to predict tumor recurrence 
in the same patient population (HR=1.68; P=1.2e-15; 
Supplementary Table 2 and Figure 3).  
 
Therefore, we conclude that these CSC-based 
mitochondrial signatures may provide a new prognostic 
approach for predicting distant metastasis and tumor 
recurrence in breast cancer patients. Most importantly, 
these results may also biologically and functionally 
implicate CSC mitochondria in the process of 
metastasis and tumor recurrence.  
 
Mitochondrial inhibitors metabolically target and 
prevent cancer cell metastasis, without significant 
toxicity 
 
To functionally evaluate the role of mitochondria in 
cancer metastasis, we used a series of mitochondrial 
inhibitors that were previously developed to specifically 
target the propagation of CSCs, known as the 
 
 
Figure 2. A CSC-based mitochondrial 13-gene signature 
predicts distant metastasis in ER(+) breast cancer 
patients. We used 13 gene transcripts to create a CSC-based 
mitochondrial-related gene signature, that effectively predicted 
distant metastasis in N=1,395 patients (HR=1.79; P=3.4e-07). See 
also Supplementary Table 1. DMFS, distant metastasis free 
survival.  
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Mitoriboscins [15]. These inhibitors were developed via 
in silico screening of a library of 45,000 compounds, to 
identify positive hits that bound to the 3D-structure of the 
large mitochondrial ribosome [15]. After 880 positive hits 
were identified, these compounds were then subjected to 
phenotypic drug screening, using an ATP-depletion assay, 
and directly validated using the Seahorse Metabolic Flux 
analyser, to confirm their specificity as bonafide 
mitochondrial inhibitors [15]. Ultimately, this screening 
approach led to the identification of three major 
compounds, known as 23/G4, 24/D4 and 24/F9, which 
all inhibited 3D-mammosphere formation in MCF7 
cells and significantly blocked cell migration in MDA-
MB-231 cells, all in the low micro-molar range [15]. 
The structures of 23/G4, 24/D4 and 24/F9 are shown in 
Figure 4.  
 
 
Figure 3. A CSC-based mitochondrial 4-gene signature predicts distant metastasis and tumor recurrence in ER(+) breast 
cancer patients. To optimize its predictive value, we constructed a short 4-gene signature, which revealed an increase in prognostic value, 
related to distant metastasis (HR=1.91; P=2.2e-08). This 4-gene signature (ACLY, VDAC3, HADH2, COX6B1) was also able to predict tumor 
recurrence in the same patient population (HR=1.68; P=1.2e-15). See also Supplementary Tables 2 and 3. Therefore, these CSC-based 
mitochondrial signatures may provide a prognostic approach for predicting treatment failure in breast cancer. DMFS, distant metastasis free 
survival; RFS, relapse free survival.  
 
 
 
Figure 4. Mitochondrial inhibitors: Mitoriboscins and Bis-1,4-butene-TPP. The chemical structures of the three Mitoriboscins 
(23/G4, 24/D4 and 24/F9) and Bis-TPP are shown.  
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To experimentally evaluate their functional effects in 
vivo, we used MDA-MB-231 cells and the well-
established chorio-allantoic membrane (CAM) assay 
in chicken eggs, to quantitatively measure tumor 
growth and distant metastasis. An inoculum of 1 X 
106 MDA-MB-231 cells was added onto the CAM of 
each egg (day E9) and then eggs were randomized 
into groups. On day E10, tumors were detectable and 
they were then treated daily for 8 days with vehicle 
alone (1% DMSO in PBS) or the three Mitoriboscin 
compounds. In parallel, we also evaluated the activity 
of another mitochondrial inhibitor, namely butane-
1,4-bis-triphenyl-phosphonium (Bis-TPP), which we 
identified as an inhibitor of 3D-mammosphere 
formation in MCF7 cells, with an IC-50 of less than 
0.5 μM [16]. It is well-established that the TPP-
moiety acts as a chemical signal for mitochondrial 
targeting [16, 17].  
 
After 8 days of drug administration, on day E18 all 
tumors were weighed, and the lower CAM was 
collected to evaluate the number of metastatic cells, as 
analyzed by qPCR with specific primers for Human Alu 
sequences.  
 
Figure 5 shows the effects of the three Mitoriboscins 
(23/G4, 24/D4, 24/F9) and Bis-TPP on MDA-MB-231 
tumor growth. Note that none of the four inhibitors 
tested showed any significant effects on tumor 
growth, as a result of the 8-day period of drug 
administration.  
However, all four mitochondrial inhibitors showed 
significant effects on MDA-MB-231 cancer cell 
metastasis. Figure 6 illustrates that all three 
Mitoriboscins were clearly effective in inhibiting 
metastatic progression, although 24/D4 and 24/F9 were 
the most effective. In addition, Bis-TPP also 
significantly prevented metastasis.  
 
As 23/G4 was minimally effective at a concentration 
of 0.5 mM, we also tested it at higher concentrations 
of 0.75, 1 and 2 mM. Importantly, our results show 
that 23/G4, at these concentrations, significantly 
inhibited both tumor growth (by 40% to 60%;  
Figure 7) and metastatic progression (by 70-75%; 
Figure 8). Interestingly, as expected, the effects of 
23/G4 on metastasis were significantly more 
pronounced.  
 
Remarkably, in this series of experiments, little or no 
embryo toxicity was observed, otherwise tumor growth 
and cancer metastasis assays could not have been 
completed (Tables 1–3). Therefore, we conclude that 
mitochondrial inhibitors can be used experimentally, to 
preferentially inhibit the initiation of tumor metastasis, 
without significant toxicity.  
 
Finally, we also tested another more potent 
mitochondrially-targeted TPP compound, namely 
Dodecyl-TPP, using low micro-molar concentrations 
(6.25- and 25-μM). Figures 9 and 10 demonstrate that 
Dodecyl-TPP significantly inhibited tumor growth (by 
 
 
 
Figure 5. Mitochondrial inhibitors have no effect on tumor growth. MDA-MB-231 cells and the well-established chorio-allantoic 
membrane (CAM) assay in chicken eggs were used to quantitatively measure tumor growth. An inoculum of 1 X 106 MDA-MB-231 cells was 
added onto the CAM of each egg (on Day E9) and then eggs were then randomized into groups. On day E10, tumors were detectable and 
they were then treated daily for 8 days with vehicle alone (1% DMSO in PBS) or the four mitochondrial inhibitors. After 8 days of drug 
administration, on day E18 all tumors were weighed. Note that none of the mitochondrial inhibitors tested had any significant effects on 
tumor growth. Averages are shown + SEM. NS, not significant.  
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12% to 40%; Figure 9) and metastatic progression (by 
25 to 65%; Figure 10). As predicted, Dodecyl-TPP 
preferentially targeted metastasis, rather than tumor 
growth. It is worth noting that Dodecyl-TPP showed 
some toxicity, but only at 62.5-μM, preventing reliable 
analysis of its effects on tumor growth and metastasis, 
at this higher concentration (Table 3). However, 
Dodecyl-TPP showed little or no toxicity at 6.25- and 
25-μM (Table 3).  
Mito-Ribosome based signatures for predicting 
distant metastasis and tumor recurrence: 
Implications as companion diagnostics 
 
Given the functional effects of the Mitoriboscin 
compounds on metastasis, we next evaluated if the gene 
mRNA transcripts of the large mitochondrial ribosomal 
proteins (MRPL) show any prognostic value in ER(+) 
and ER(-)/basal breast cancer patients.  
 
 
 
Figure 6. Mitochondrial inhibitor compounds selectively target and prevent cancer metastasis. MDA-MB-231 cells and the well-
established chorio-allantoic membrane (CAM) assay in chicken eggs were used to quantitatively measure spontaneous tumor mestastasis.  
An inoculum of 1 X 106 MDA-MB-231 cells was added onto the CAM of each egg (on day E9) and then eggs were then randomized into 
groups. On day E10, tumors were detectable and they were then treated daily for 8 days with vehicle alone (1% DMSO in PBS) or the four 
mitochondrial inhibitors. After 8 days of drug administration, the lower CAM was collected to evaluate the number of metastatic cells, as 
analyzed by qPCR with specific primers for Human Alu sequences. Note that all four mitochondrial inhibitors showed significant effects on 
MDA-MB-231 metastasis. More specifically, all three Mitoriboscins were clearly effective in inhibiting metastasis, although 24/D4 and 24/F9 
were the most effective. In addition, Bis-TPP also significantly prevented metastasis. Averages are shown + SEM. *p<0.05; ***p<0.001. 
 
 
 
Figure 7. Effects of the Mitoriboscin 23/G4 on tumor growth. The Mitoriboscin 23/G4 was tested at higher concentrations of 0.75, 1 
and 2 mM. Note that 23/G4, at these concentrations, inhibited tumor growth (by 40% to 60%). Averages are shown + SEM. ***p<0.001. 
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Table 1. Chick embryo toxicity of Mitoriboscins and Bis-TPP at a concentration of 0.5 mM.  
Group #  Group      Description                   Total  Alive  Dead  % Alive  % Dead  
1  Neg. Ctrl.                   18  16  2  88.89  11.11  
2  23/G4                   10  7  3  70  30  
3  24/D4                   12  12  0  100  0  
4  24/F9                   10  8  2  80  20  
5  Bis-TPP                   12  7  5  58.33  41.67  
Table 2. Chick embryo toxicity of Mitoriboscin 23/G4 at higher concentrations.  
Group # Group  Description   Total       Alive        Dead  % Alive  % Dead  
1  Neg. Ctrl.      17         12           5  70.59  29.41  
2 23/G4 [0.75 mM]      14         10           4  71.43  28.57  
3  23/G4 [1 mM]      15         12           3  80  20  
4 23/G4 [2 mM]      15         10           5  66.67  33.33  
Table 3. Chick embryo toxicity of Dodecyl-TPP.  
Group #  Group  Description   Total        Alive         Dead  % Alive  % Dead  
1  Neg. Ctrl.   18          13            5  72.22   27.78  
2  d-TPP [6.25 μM]   19          13            6  68.42   31.58  
3  d-TPP [25 μM]   19          13            6  68.42   31.58  
4  d-TPP [62.5 μM]   19            3           16  15.79   84.21  
 
In ER(+) breast cancer, a 9-gene mito-ribosome signature 
was able to effectively predict distant metastasis in 
N=1,395 patients (HR=1.59; P=5e-05) and tumor 
recurrence in N=3,082 patients (HR=1.71; P<1e-16) (See 
Supplementary Tables 4 and 5; Figure 11). Importantly, 
a closely related mito-ribosome signature was also 
able to predict treatment failure in a sub-set of ER(+) 
patients undergoing Tamoxifen treatment, which 
resulted in distant metastasis (N=618 patients; 
HR=2.16; P=1.7e-05) and tumor recurrence (N=799 
patients; HR=3.45; P=1.6e-08) (Supplementary 
Tables 6 and 7; Figure 12).  
 
 
 
Figure 8. Effects of the Mitoriboscin 23/G4 on cancer metastasis. The Mitoriboscin 23/G4 was tested at higher concentrations, 
namely 0.75, 1 and 2 mM. Note that 23/G4, at these concentrations, significantly inhibited metastasis (by 70-75%). Interestingly, the 
effects of 23/G4 on metastasis were significantly more pronounced than its effects on tumor growth. Averages are shown + SEM. 
***p<0.001. 
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In ER(-)/basal breast cancer, a distinct 6-gene mito-
ribosome MRPL signature was also able to effectively 
predict distant metastasis in N=145 patients (HR=2.95; 
P=0.0018) and tumor recurrence in N=360 patients 
(HR=2.19; P=1.9e-06), as well as overall survival in 
N=153 patients (HR=3.17; P=0.00033) (Supplementary 
Table 8; Figures 13 and 14). 
 
In summary, these short mito-ribosome gene signatures 
may also be useful as companion diagnostics to assess 
which patient populations may benefit most from the 
administration of the Mitoriboscin compounds.  
 
DISCUSSION 
 
Current thinking indicates that CSCs are the etiological 
cause of treatment failure in most cancer patients, as 
they are the cellular drivers of tumor recurrence, 
metastasis and drug-resistance [1–5]. As a consequence, 
new therapeutic approaches are needed to effectively 
eliminate CSCs. Our previous studies identified CSC 
mitochondria as a potential new therapeutic target. 
More specifically, we experimentally observed that  
 
 
 
Figure 9. Effects of Dodecyl-TPP on tumor growth. 
Dodecyl-TPP, another more potent mitochondrially-targeted 
TPP compound, was tested using low micro-molar 
concentrations (6.25- and 25-μM). Note that Dodecyl-TPP 
significantly inhibited tumor growth (by 12% to 40%). 
Averages are shown + SEM. *p<0.05; ***p<0.001. The 
structure of Dodecyl-TPP (d-TPP) is also shown. Note the 12-
carbon alkyl-chain attached to the lipophilic cation, triphenyl-
phosphonium (TPP). 
MCF7-derived 3D-mammospheres are specifically 
enriched in mitochondrial proteins; 25 mitochondrial 
proteins showed greater than 100-fold over-
expression, while 9 of these proteins were infinitely 
up-regulated, as compared with 2D-monolayers [6]. In 
this report, we used these proteomic data as possible 
candidates to generate short mitochondrial gene 
signatures that could be employed as prognostic tools 
to predict distant metastasis (in N=1,395 patients) and 
tumor recurrence (in N=3,082 patients), in a large 
collection of ER(+) breast cancer patients. For 
example, we developed a 4-gene signature for 
predicting distant metastasis, resulting in a hazard 
ratio of 1.91-fold (P=2.2e-08). This clinical evidence 
supports the idea that CSC mitochondria may play a 
critical functional role in the metastatic dissemination 
of cancer cells.  
 
To further test this hypothesis experimentally, we next 
employed a well-established animal model, namely the 
chorio-allantoic membrane (CAM) in chicken eggs, to 
test a series of mitochondrial inhibitors. These mito-
chondrial inhibitors, including the Mitoriboscins, have 
been previously described to effectively inhibit 3D-
mammosphere formation in MCF7 cells and cell 
migration in MDA-MB-231 cells. All five of these  
 
 
 
Figure 10. Effects of Dodecyl-TPP on cancer metastasis. 
Dodecyl-TPP was tested using low micro-molar concentrations 
(6.25- and 25-µM). Note that Dodecyl-TPP significantly 
inhibited metastasis (by 25% to 65%). Averages are shown 
+ SEM. *p<0.05; ***p<0.001. Importantly, little or no toxicity 
was observed for Dodecyl-TPP at 6.25- and 25-μM (Table 3). 
The structure of Dodecyl-TPP (d-TPP) is also shown. 
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Figure 11. A large mito-ribosome 9-gene signature predicts metastasis and recurrence in ER(+) breast cancer patients. A 9-
gene mito-ribosome signature effectively predicts distant metastasis in N=1,395 patients (HR=1.59; P=5e-05) and tumor recurrence in 
N=3,082 patients (HR=1.71; P<1e-16). See Supplementary Tables 4 and 5. DMFS, distant metastasis free survival; RFS, relapse free survival. 
 
 
Figure 12. A large mito-ribosome gene signature predicts metastasis and recurrence in ER(+) breast cancer patients, treated 
with Tamoxifen. A mito-ribosome signature predicts treatment failure in a sub-set of ER(+) patients undergoing Tamoxifen treatment, 
which resulted in distant metastasis (N=618 patients; HR=2.16; P=1.7e-05) and tumor recurrence (N=799 patients; HR=3.45; P=1.6e-08). See 
also Supplementary Tables 6 and 7. DMFS, distant metastasis free survival; RFS, relapse free survival. 
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Figure 13. A large mito-ribosome gene signature predicts distant metastasis and tumor recurrence in ER(-)/basal breast 
cancer patients. In ER(-)/basal breast cancer, a 6-gene mito-ribosome signature was also able to effectively predict distant metastasis in 
N=145 patients (HR=2.95; P=0.0018) and tumor recurrence in N=360 patients (HR=2.19; P=1.9e-06). See also Supplementary Table 8. 
 
 
Figure 14. A large mito-ribosome gene signature predicts overall survival in ER(-)/basal breast cancer patients. In ER(-)/basal 
breast cancer, a 6-gene mito-ribosome signature was also able to effectively predict overall survival in N=153 patients (HR=3.17; P=0.00033). 
OS, overall survival. 
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mitochondrial inhibitors selectively prevented MDA-
MB-231 tumor cell metastasis, but had only minor 
effects or no effect on tumor formation. More 
specifically, we have previously shown that these 
mitochondrial inhibitors successfully induce ATP-
depletion in cancer cells, by targeting mitochondrial 
protein translation and/or OXPHOS activity [15–17]. 
Our current studies provide the necessary in vivo 
functional evidence, that mitochondrial inhibitors can 
successfully prevent cancer metastasis. These findings 
could have important clinical implications,  
for ultimately preventing treatment failure in breast 
cancer patients, via metastasis prophylaxis (Figure 
15).  
 
Since the Mitoriboscins were originally engineered to 
inhibit the large mitochondrial ribosome [15], we 
also focused on whether the large mitochondrial 
ribosomal gene transcripts (MRPL) have any 
prognostic value, for predicting distant metastasis in 
ER(+) breast cancer patients. Importantly, signatures 
containing MRPL gene transcripts were effective in 
predicting metastasis, recurrence and Tamoxifen-
resistance. Similar results were also obtained in ER(-) 
breast cancer patients. As a consequence of the 
success of this approach, these MRPL gene 
signatures may ultimately be useful as new 
companion diagnostics, to guide decisions to 
determine which patients would benefit from anti-
mito-ribosome therapy.  
 
 
 
Figure 15. Metastasis prophylaxis: Clinical implications 
of mitochondrial inhibitors for the prevention of 
treatment failure and cancer metastasis. Based on our 
current results, that mitochondrial inhibitors can selectively 
prevent metastasis, we suggest that these findings could be 
applied clinically to help prevent treatment failure in breast 
cancer patients.  
MATERIALS AND METHODS 
 
Materials 
 
MDA-MB-231 cells, a human breast cancer cell line, 
were obtained from the American Type Culture 
Collection (ATCC). Mitoriboscins (23/G4, 24/D4, 
24/F9), Butene-1,4-bis-triphenyl-phosphonium (Bis-
TPP), and Dodecyl-TPP, were all as we previously 
described [15–17].  
 
Kaplan-Meier (K-M) analyses  
 
To perform K-M analysis on gene transcripts, we used 
an open-access online survival analysis tool to 
interrogate publically available microarray data from up 
to 3,951 breast cancer patients (18). This allowed us to 
determine their prognostic value. For this purpose, we 
primarily analyzed data from ER(+)s and ER(-)/basal 
patients. Biased array data were excluded from the 
analysis. This allowed us to identify mitochondrial gene 
transcripts, with significant prognostic value. Hazard-
ratios were calculated, at the best auto-selected cut-off, 
and p-values were calculated using the Log-rank test 
and plotted in R. K-M curves were also generated 
online using the K-M-plotter (as high-resolution TIFF 
files), using univariate analysis: https://kmplot.com/ 
analysis/index.php?p=service&cancer=breast. 
 
This approach allowed us to directly perform in silico 
validation of these mitochondrial biomarker candidates. 
The multi-gene classifier function of the program was 
used to test the prognostic value of short mitochondrial 
gene signatures, using the mean expression of the 
selected probes. The latest 2020 version of the database 
was utilized for all these analyses. 
 
Assays for tumor growth, metastasis and embryo 
toxicity 
 
Preparation of chicken embryos  
Fertilized White Leghorn eggs were incubated at 37.5°C 
with 50% relative humidity for 9 days. At that moment 
(E9), the chorioallantoic membrane (CAM) was 
dropped down by drilling a small hole through the 
eggshell into the air sac, and a 1 cm² window was cut in 
the eggshell above the CAM (19-23). 
 
Amplification and grafting of tumor cells  
The MDA-MB-231 tumor cell line was cultivated in 
DMEM medium supplemented with 10% FBS and 1% 
penicillin/streptomycin. On day E9, cells were detached 
with trypsin, washed with complete medium and 
suspended in graft medium. An inoculum of 1 X 106 
cells was added onto the upper CAM of each egg (E9) 
and then eggs were randomized into groups [19–23]. 
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Tumor growth assays  
At day 18 (E18), the upper portion of the CAM was 
removed from each egg, washed in PBS and then 
directly transferred to paraformaldehyde (fixation for 48 
h) and weighed [19–23]. For tumor growth assays, at 
least 8 tumor samples were collected and analysed per 
group (n > 8). 
 
Metastasis assays  
On day E18, a 1 cm² portion of the lower CAM was 
collected to evaluate the number of metastatic cells in 8 
samples per group (n=8). Genomic DNA was extracted 
from the CAM (commercial kit) and analyzed by qPCR 
with specific primers for Human Alu sequences. 
Calculation of Cq for each sample, mean Cq and 
relative amounts of metastases for each group are 
directly managed by the Bio-Rad® CFX Maestro 
software. A one-way ANOVA analysis with post-tests 
was performed on all the data [19–23]. 
 
Embryo tolerability assays 
Before each administration, the treatment tolerability 
was evaluated by scoring the number of dead embryos. 
This approached is summarized schematically in 
Supplementary Figures 1 and 2.  
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SUPPLEMENTARY MATERIALS 
 
Supplementary Figures 
 
 
 
 
 
 
 
Supplementary Figure 1. Summary: The Chorio-allantoic Membrane (CAM) Method. Fertilized White Leghorn eggs were as used 
the xenograft host for growing human MDA-MB-231 cells to measure i) tumor growth (weight), ii) metastatic invastion/progression (by qPCR 
with specific primers for Human Alu sequences) and iii) drug toxicity (by evaluating chicken embryo viability). MDA-MB-231 cells were 
implanted on embryonic day 9 (E9). Then, tumor growth and metastasis were evaluated on embryonic day 18 (E18). Treatments were 
administered for 8 days, from E10 till E17. Using this approach, the efficacy and toxicity of five mitochondrial inhibitors were evaluated, in an 
in vivo setting: Mitoriboscins (23/G4, 24/D4, 24/F9) and TPP compounds (Bis-TPP and Dodecyl-TPP). See Materials & Methods for specific 
details.  
 
 
Supplementary Figure 2. Measuring Distant Metastasis with the CAM Method. Spontaneous metastasis from the primary tumor 
located in the Upper CAM was measured by quantitating the amount of metastatic cells that accumulated in the Lower CAM region, after a 
period of 9 days, post-tumor cell implantation, using qPCR analysis. Importantly, metastatic dissemination, from the Upper CAM to the Lower 
CAM, requires cell migration, invasion, intravasation, extravasation and the formation of secondary lesions.  
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Supplementary Tables 
 
Supplementary Table 1. Distant metastasis signature (13 genes): prognostic palue of mitochondrial-related proteins 
up-regulated in MCF7 mammospheres, evaluated in ER(+) breast cancer patients (DMFS/ER(+)/N=1,395/>240-
months). 
Probe         Symbol        HR (DMFS) Log-rank test 
201128_s_at        ACLY      1.72 3.1e-05 
208845_at        VDAC3      1.66 1.2e-05 
202282_at        HADH2      1.58 7.2e-05 
201441_at         COX6B1      1.53 0.00017 
201322_at        ATP5B      1.43 0.0016 
218440_at         MCCC1      1.40 0.0054 
218275_at          SLC25A10      1.37 0.0048 
205217_at         TIMM8A      1.37 0.0072 
200789_at        ECH1      1.35 0.0092 
212186_at        ACACA      1.34 0.031 
200690_at         HSPA9      1.29 0.046 
217720_at         CHCHD2      1.28 0.028 
217814_at         CCDC47      1.28 0.032 
Combined       1.79 3.4e-07 
 
Supplementary Table 2. Distant metastasis signature (4 genes): prognostic value of mitochondrial-related proteins 
up-regulated in MCF7 mammospheres, evaluated in ER(+) breast cancer patients (DMFS/ER(+)/N=1,395/>240-
months). 
Probe Symbol HR (DMFS) Log-rank test 
201128_s_at ACLY 1.72 3.1e-05 
208845_at VDAC3 1.66 1.2e-05 
202282_at HADH2 1.58 7.2e-05 
201441_at COX6B1 1.53 0.00017 
Combined  1.91 2.2e-08 
 
Supplementary Table 3. Tumor recurrence signature (4 genes): prognostic value of mitochondrial-related proteins 
up-regulated in MCF7 mammospheres, evaluated in ER(+) breast cancer patients (RFS/ER(+)/N=3,082/>240-months). 
Probe Symbol HR (RFS) Log-rank test 
208845_at VDAC3 1.56 2.3e-11 
202282_at HADH2 1.52 1.3e-09 
201441_at COX6B1 1.51 1.3e-10 
201128_s_at ACLY 1.12 0.091 
Combined  1.68 1.2e-15 
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Supplementary Table 4. Distant metastasis signature (9 genes): prognostic value of large mito-ribosomal proteins, 
evaluated in ER(+) breast cancer patients (DMFS /ER(+)/N=1,395/>240-months). 
Probe Symbol HR (DMFS) Log-rank test 
218027_at MRPL15 1.68 4.1e-06 
218049_s_at MRPL13 1.56 8.8e-05 
222216_s_at MRPL17 1.53 0.00044 
219244_s_at MRPL46 1.46 0.0013 
217907_at MRPL18 1.40 0.005 
218281_at MRPL48 1.38 0.0078 
208787_at MRPL3 1.37 0.0086 
218270_at MRPL24 1.33 0.021 
218105_s_at MRPL4 1.29 0.023 
Combined  1.59 5e-05 
 
Supplementary Table 5. Tumor recurrence signature (9 genes): prognostic value of large mito-ribosomal proteins, 
evaluated in ER(+) breast cancer patients (RFS /ER(+)/N=3,082/>240-months). 
Probe Symbol HR (RFS) Log-rank test 
218027_at MRPL15 1.72 <1e-16 
218049_s_at MRPL13 1.71 <1e-16 
208787_at MRPL3 1.71 <1e-16 
222216_s_at MRPL17 1.70 1.1e-16 
217907_at MRPL18 1.55 2e-11 
218281_at MRPL48 1.26 0.00041 
218105_s_at MRPL4 1.24 0.00095 
219244_s_at MRPL46 1.21 0.0083 
218270_at MRPL24 1.10 0.2 
Combined  1.71 <1e-16 
 
Supplementary Table 6. Distant metastasis signature (6 genes): prognostic value of large mito-ribosomal proteins, 
evaluated in ER(+) breast cancer patients (DMFS /ER(+)/N=618/>240-months) treated with Tamoxifen. 
Probe                    Symbol                HR (DMFS) Log-rank test 
218027_at                   MRPL15                2.15   1.7e-06 
219244_s_at                   MRPL46               1.99   0.00011 
222216_s_at                   MRPL17               1.99   0.0036 
218270_at                   MRPL24               1.94   0.00024 
217907_at                   MRPL18               1.71   0.0051 
218049_s_at                  MRPL13               1.55   0.021 
Combined                2.16   1.7e-05 
 
Supplementary Table 7. Tumor recurrence signature (8 genes): prognostic value of large mito-ribosomal proteins, 
evaluated in ER(+) breast cancer patients (RFS /ER(+)/N=799/>240-months) treated with Tamoxifen. 
Probe Symbol HR (RFS) Log-rank test 
218027_at MRPL15 2.20 7.8e-08 
208787_at MRPL3 2.04 0.00015 
222216_s_at MRPL17 2.01 2.3e-06 
217907_at MRPL18 1.92 9.1e-06 
218270_at MRPL24 1.77 0.00012 
218049_s_at MRPL13 1.66 0.0059 
218281_at MRPL48 1.55 0.0033 
219244_s_at MRPL46 1.53 0.0063 
Combined  3.45 1.6e-08 
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Supplementary Table 8. Distant metastasis signature (6 genes): prognostic value of large mito-ribosomal proteins, 
evaluated in ER(-)/basal breast cancer patients (DMFS/N=145/>120-months). 
Probe          Symbol         HR (DMFS) Log-rank test 
222466_s_at          MRPL42       4.00 0.0024 
227186_s_at          MRPL41      3.43 0.0023 
225797_at          MRPL54      2.44 0.011 
218049_s_at         MRPL13      2.23 0.0022 
224331_s_at         MRPL36      2.13 0.036 
218339_at         MRPL22      1.75 0.029 
Combined       2.95 0.0018 
 
